Wolfe Research Initiates Coverage on GSK (NYSE:GSK)

by · The Markets Daily

Investment analysts at Wolfe Research started coverage on shares of GSK (NYSE:GSK – Get Free Report) in a research report issued to clients and investors on Friday, Briefing.com reports. The firm set an “outperform” rating and a $70.00 price target on the pharmaceutical company’s stock. Wolfe Research’s price objective would suggest a potential upside of 50.48% from the company’s current price.

Several other equities research analysts also recently commented on GSK. Morgan Stanley reiterated an “underweight” rating on shares of GSK in a research report on Tuesday, August 25th. HSBC restated a “hold” rating on shares of GSK in a research report on Thursday, September 10th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a report on Thursday, July 30th. Wall Street Zen cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Royal Bank Of Canada began coverage on GSK in a report on Tuesday, September 8th. They issued a “sector perform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $61.00.

Read Our Latest Stock Analysis on GSK

GSK Price Performance

GSK stock opened at $46.52 on Friday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. GSK has a 52 week low of $42.85 and a 52 week high of $61.69. The stock has a market capitalization of $94.09 billion, a P/E ratio of 14.55, a price-to-earnings-growth ratio of 2.11 and a beta of 0.33. The stock has a fifty day moving average of $50.12 and a 200-day moving average of $51.87.

GSK (NYSE:GSK – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.09. The business had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. GSK had a return on equity of 43.23% and a net margin of 14.56%.GSK’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $0.47 earnings per share. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. On average, sell-side analysts expect that GSK will post 4.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GSK

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nvest Financial LLC acquired a new stake in GSK in the second quarter valued at approximately $2,236,000. Kahn Brothers Group Inc. acquired a new position in shares of GSK during the second quarter worth approximately $8,305,000. Keystone Financial Planning Inc. lifted its holdings in shares of GSK by 3,114.8% in the 2nd quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock worth $10,253,000 after purchasing an additional 189,506 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of GSK by 842.9% in the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock worth $49,986,000 after purchasing an additional 852,437 shares in the last quarter. Finally, Dorsey Wright & Associates acquired a new stake in GSK in the 1st quarter valued at $2,522,000. 15.74% of the stock is owned by institutional investors.

GSK Company Profile

(Get Free Report)

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.

Featured Stories